CAS 54631-24-2

DL-threo-Ritalinic Acid

Produit contrôlé

CAS : 54631-24-2

Formule : C₁₃H₁₇NO₂

Couleur et forme : Neat

Masse moléculaire : 219.28

Ref: TR-R533120

DL-threo-Ritalinic Acid Hydrochloride

Produit contrôlé

CAS : 54631-24-2

Formule : C₁₃H₁₈ClNO₂

Couleur et forme : Neat

Masse moléculaire : 255.74

Ref: TR-R533110

DL-threo-Ritalinic Acid (1 mg/ml in Acetonitrile)

Produit contrôlé

CAS : 54631-24-2

Formule : C₁₃H₁₇NO₂

Couleur et forme : Single Solution

Masse moléculaire : 219.28

Ref: TR-KIT7160

DL-threo-Ritalinic Acid Hydrochloride (1mg/ml in Acetonitrile)

Produit contrôlé

CAS : 54631-24-2

Formule : C₁₃H₁₈ClNO₂

Couleur et forme : Single Solution

Masse moléculaire : 255.74

Ref: TR-KIT7155

DL-threo-Ritalinic acid

CAS : 54631-24-2

Formule : C₁₃H₁₇NO₂

Couleur et forme : Solid

Masse moléculaire : 219.2796

Ref: IN-DA003AJP

DL-threo-Ritalinic acid

Produit contrôlé

CAS : 54631-24-2

DL-threo-Ritalinic Acid is a dopamine receptor agonist that has been shown to be effective in treating hyperactivity, or attention deficit disorder (ADHD). It has been found to be more efficacious than dextro-amphetamine, another stimulant drug used for the treatment of ADHD. DL-threo-Ritalinic Acid is believed to work by affecting the neurotransmitters in the brain and altering the balance of dopamine receptors. In a two-way crossover study, preschool children were given either 0.5mg/kg of DL-threo-Ritalinic Acid or placebo for three days. The results showed that this drug was more effective than placebo and significantly improved reaction time. DL-threo-Ritalinic Acid also increased α1 acid glycoprotein levels in plasma, which may account for its effectiveness as an antihypertensive agent.

Formule : C₁₃H₁₇NO₂

Degré de pureté : Min. 95%

Masse moléculaire : 219.28 g/mol

Ref: 3D-IR180350